• A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

  NCT07201922

  RecruitingInterventionalPhase 3Updated Aug 18, 2026
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

  NCT05321082

  CompletedInterventionalPhase 3Updated Jan 9, 2026
• A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

  NCT07366034

  RecruitingInterventionalPhase 3Updated Aug 18, 2026
• A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622

  RecruitingInterventionalPhase 3Updated Aug 20, 2026
• A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

  NCT06806592

  RecruitingInterventionalPhase 3Updated Aug 20, 2026
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069

  CompletedInterventionalPhase 3Updated Oct 20, 2025

ClinicalTrials.gov ID

NCT07540988

Lead Sponsor

Boehringer IngelheimINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

466Estimated

Last Update Posted

Aug 20, 2026Actual

Start Date

Aug 28, 2026Estimated

Primary Completion Date

Dec 5, 2028Estimated

Completion Date

Dec 12, 2028Estimated

Official Title

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

Brief Summary

This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse.

Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression.

Participants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

• Interstitial Lung Diseases

• Nerandomilast
• Placebo matching nerandomilast

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion criteria :

1. Male and female individuals ≥18 years of age at the time of first signed informed consent at Visit 1a
2. Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) and local legislation prior to admission to the trial
3. Diagnosis of fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) as established by the investigator
4. Presence of fibrotic lung disease on high resolution computed tomography (HRCT), defined as reticulation with traction bronchiectasis/ bronchiolectasis and/or honeycombing, and extent of fibrosis ≥10%, as assessed by central review prior to randomization
5. Time since ILD diagnosis ≤3 years before randomization
6. FVC ≥45% of predicted normal at Visit 1
7. Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥25% of predicted normal corrected for hemoglobin (Hb) at Visit 1
8. Patients treated with permitted immunosuppressive/immunomodulatory agents for an underlying systemic disease (e.g. methotrexate (MTX), azathioprine (AZA)) need to be on stable treatment for at least 12 weeks prior to Visit 1 and during screening period
9. Further inclusion criteria apply.

Exclusion criteria :

1. Known diagnosis of idiopathic pulmonary fibrosis (IPF) based on multidisciplinary discussion (MDD) and according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2022 guidelines
2. Known diagnosis of autoimmune-ILDs other than rheumatoid arthritis-associated ILD (RA-ILD)
3. Known diagnosis of sarcoidosis
4. Patients with predominant features of organizing pneumonia on HRCT, as assessed by central review
5. Patients who developed ILD due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection/Coronavirus Disease 2019 (COVID-19) (based on investigators judgement)
6. Meeting criteria for progressive pulmonary fibrosis (PPF), as assessed by investigator
7. Meeting criteria for treatment with currently approved therapies for the fibrosing ILD (e.g. PPF), as assessed by investigator
8. Prior or current use of nerandomilast, nintedanib, or pirfenidone
9. Further exclusion criteria apply.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Boehringer IngelheimINDUSTRY

unitedstates@bitrialsupport.com833-602-2368

argentina@bitrialsupport.com08002667801

argentina@bitrialsupport.com08002667801

oesterreich@bitrialsupport.com0800017900

oesterreich@bitrialsupport.com0800017900

oesterreich@bitrialsupport.com0800017900

oesterreich@bitrialsupport.com0800017900

oesterreich@bitrialsupport.com0800017900

belgique@bitrialsupport.com080049616

belgique@bitrialsupport.com080049616

brasil@bitrialsupport.com08008919295

brasil@bitrialsupport.com08008919295

canada@bitrialsupport.com18336022346

china@bitrialsupport.com4001200553

china@bitrialsupport.com4001200553

china@bitrialsupport.com4001200553

china@bitrialsupport.com4001200553

china@bitrialsupport.com4001200553

china@bitrialsupport.com4001200553

china@bitrialsupport.com4001200553

suomi@bitrialsupport.com0800918118

suomi@bitrialsupport.com0800918118

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

france@bitrialsupport.com0805102354

deutschland@bitrialsupport.com08007234742

deutschland@bitrialsupport.com08007234742

deutschland@bitrialsupport.com08007234742

deutschland@bitrialsupport.com08007234742

deutschland@bitrialsupport.com08007234742